Pay in 4 interest-free payments of $5.89 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Abstract Objective The aim was to evaluate the cost-effectiveness of oral and subcutaneous semaglutide versus other oral glucose-lowering drugs (i.e., empagliflozin, canagliflozin, and sitagliptin) for the management of type 2 diabetes (T2D) in Denmark using clinically relevant treatment intensification rules
Schneider SL, Tosti A
convenient locations Table of Contents: What are tirzepatide injections
1997;100(6 Pt 1):734-738
US$ 23.57
US$ 27.00
US$ 24.64
US$ 25.54
US$ 22.40
